CRISPR Collaboration Agreement - Additional Information (Details) - Research Collaboration Agreement		3 Months Ended		9 Months Ended
	May 05, 2021 CrisprCas9	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Development and Regulatory Approval Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reduction of research and development expense resulting from partial reimbursement		$ 300,000	$ 1,000,000	$ 1,400,000	$ 2,800,000
Receivable under research cost sharing provision		$ 300,000		$ 300,000
Potential future payments				totaling less than mid-twenty million dollars
Amount paid under the agreement				$ 0
Amounts owed under the agreement				$ 0
NK Cell Products
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of non-exclusive rights to gene editing targets licenses received | CrisprCas9	4
NK Cell Products | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of non-exclusive rights to gene editing targets | CrisprCas9	1
Specified TA | Development and Regulatory Approval Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential future payments				totaling less than high-forty million dollars